EIF4E and breast carcinoma: Among various NRs, lead racemic VNLG-152 (4-(±)-(1H-imidazol-1-yl)-N-(4-fluorophenyl)-(E)-retinamide; termed VNLG-152R; Figure 1A) exhibited exemplary Mnk-eIF4E/m-TORC1 inhibitory and in vitro anticancer activities in a variety of breast cancer subtypes [39].